New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue

New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects
Pre-Adolescents to Adults Against Dengue

- The highest burden of dengue disease globally in endemic countries is in pre-adolescent to adults age group[1],[2],[3] -

• In a new pooled analysis, dengue vaccine candidate protected two out of three volunteers aged 9 years and older against all four dengue serotypes

• Protection against severe dengue reached 93% and prevention of hospitalizations due to dengue 80% in this age group

- Based on this clinical profile in 9 years of age and older, the dengue vaccine candidate has the potential to significantly reduce disease burden in endemic countries -

Lyon, France, - July 27, 2015 - Sanofi Pasteur, the vaccines division of Sanofi, announced today that new data analyses published in the New England Journal of Medicine (NEJM) provide a comprehensive picture of the potential public health impact of vaccinating endemic populations from pre-adolescence to adulthood against dengue. Not only is this the largest population at risk of dengue globally, but individuals 9 years of age and older also represent a highly mobile group capable of spreading disease more broadly during outbreaks and also contributing substantially to the economic burden of dengue, for example in number of lost school and work days due to the disease.

The NEJM article reported results from a new pooled efficacy analysis of individuals 9 years of age and older at vaccination from the two Phase III studies of Sanofi Pasteur's dengue vaccine. The new analysis documented that the vaccine protects two-thirds of these individuals (66%) against dengue, providing even greater protection against two clinically-relevant manifestations of dengue, namely severe dengue (93%) and prevention of hospitalizations due to dengue (80%) that account for the greatest human and economic burden of dengue in endemic countries. In addition, the dengue vaccine candidate protected volunteers 9 years of age and older who were previously exposed to dengue (82%), as well as those who were naïve to dengue (52.5%) prior to vaccination.